These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 31145074)

  • 21. Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.
    Fiset PO; Shapera S; Butler MO; Tsao MS
    Ann Oncol; 2016 Aug; 27(8):1649-50. PubMed ID: 27091805
    [No Abstract]   [Full Text] [Related]  

  • 22. Pembrolizumab-associated ocular myasthenia gravis.
    Liu Q; Ayyappan S; Broad A; Narita A
    Clin Exp Ophthalmol; 2019 Aug; 47(6):796-798. PubMed ID: 30859689
    [No Abstract]   [Full Text] [Related]  

  • 23. Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma.
    Durães J; Coutinho I; Mariano A; Geraldo A; Macário MC
    Mult Scler; 2019 Jun; 25(7):1005-1008. PubMed ID: 30311534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
    Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy.
    Irimada M; Fujimura T; Kambayashi Y; Tsukada A; Takahashi T; Hashimoto A; Aiba S
    J Dermatol; 2019 Jul; 46(7):e256-e258. PubMed ID: 30656733
    [No Abstract]   [Full Text] [Related]  

  • 26. Lichen planus in a patient treated with pembrolizumab for metastatic malignant melanoma.
    Denny J; Chong H; Akhras V
    Clin Exp Dermatol; 2018 Apr; 43(3):354-356. PubMed ID: 29222829
    [No Abstract]   [Full Text] [Related]  

  • 27. Multiple "halo nevi" occurring during pembrolizumab treatment for metastatic melanoma.
    Nicolétis-Lombart I; Kervarrec T; Zaragoza J; Machet MC; Samimi M
    Int J Dermatol; 2019 Jun; 58(6):739-741. PubMed ID: 30229873
    [No Abstract]   [Full Text] [Related]  

  • 28. Alopecia areata induced by adjuvant treatment with alpha-interferon in malignant melanoma?
    Radny P; Bauer J; Caroli UM; Eigentler TK; Kamin A; Metzler G; Garbe C
    Dermatology; 2004; 209(3):249-50. PubMed ID: 15459547
    [No Abstract]   [Full Text] [Related]  

  • 29. Generalized morphea in the setting of pembrolizumab.
    Cheng MW; Hisaw LD; Bernet L
    Int J Dermatol; 2019 Jun; 58(6):736-738. PubMed ID: 29931792
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunotherapy-induced colitis: Could it be ulcerative colitis?
    Moreno Moraleda I; Lázaro Sáez M; Diéguez Castillo C; Hernández Martínez Á
    Gastroenterol Hepatol; 2021 Jan; 44(1):28-29. PubMed ID: 32873419
    [No Abstract]   [Full Text] [Related]  

  • 31. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
    Woodbeck R; Metelitsa AI; Naert KA
    Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
    Kähler KC; Kosova K; Bohne AS; Schreiber S; Hauschild A
    Eur J Cancer; 2020 Oct; 138():169-171. PubMed ID: 32890812
    [No Abstract]   [Full Text] [Related]  

  • 33. Novel therapies for unresectable and metastatic melanoma.
    Karimkhani C; Reddy BY; Dellavalle RP; Sundararajan S
    BMJ; 2017 Nov; 359():j5174. PubMed ID: 29191943
    [No Abstract]   [Full Text] [Related]  

  • 34. Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma.
    Russo I; Filoni A; Alaibac M
    Eur J Dermatol; 2021 Feb; 31(1):99-100. PubMed ID: 33586650
    [No Abstract]   [Full Text] [Related]  

  • 35. Fulminant type 1 diabetes mellitus associated with pembrolizumab.
    Mizab Mellah C; Sánchez Pérez M; Santos Rey MD; Hernández García M
    Endocrinol Diabetes Nutr; 2017 May; 64(5):272-273. PubMed ID: 29056250
    [No Abstract]   [Full Text] [Related]  

  • 36. Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia.
    Arenbergerova M; Fialova A; Arenberger P; Gkalpakiotis S; Jirasek T; Srp A; Novotna A; Frankova H
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):e72-e74. PubMed ID: 28833722
    [No Abstract]   [Full Text] [Related]  

  • 37. Pembrolizumab-induced autoimmune encephalitis in a woman with lentiginous melanoma.
    Omizzolo L
    Emergencias; 2024 Jun; 36(4):319. PubMed ID: 39234842
    [No Abstract]   [Full Text] [Related]  

  • 38. A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia.
    Berger M; Amini-Adlé M; Crumbach L; Paubelle E; Dalle S
    Eur J Cancer; 2019 Mar; 110():49-52. PubMed ID: 30739840
    [No Abstract]   [Full Text] [Related]  

  • 39. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
    Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
    Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
    [No Abstract]   [Full Text] [Related]  

  • 40. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.
    Hammami MB; Gill R; Thiruvengadam N; Oh DY; Beck K; Mahadevan U; Kattah MG
    Dig Dis Sci; 2019 Mar; 64(3):685-688. PubMed ID: 30778872
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.